PHAXIAM announces that it has received two bids as part of a disposal plan, following the bidding process (appel d’offres) launched within the framework of the receivership procedure opened on March 6, 2025.
Read morefollowing the Company’s request, the Commercial Court of Lyon decided on March 6, 2025, to open a judicial receivership procedure.
Read morePHAXIAM has requested Euronext to suspend the trading of its stock listed on the Euronext Paris market
Read moreStrategy built around two complementary development axes: GMP Individualized Phage Therapies (IPT) and Phage Therapies Medicinal Products (PTMP)
Read moreOn Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections
Read morePromising clinical results observed in the first 88 patients evaluated so far
Read moreThis non-comparative pilot study, including patients with Prosthetic Joint Infections (PJI), recruited 29 patients, 26 of whom were evaluable
Read moreWebinar being held today “Evolving strategic context for phages, Introducing new opportunities” to present PHAXIAM Therapeutics strategy
Read moreorganized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scale
Read moreCash and cash equivalents of €5.7 million as of September 30, 2024
Read more
